 SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 GLOBE NEWSWIRE -- Cytokinetics, Incorporated Nasdaq: CYTK today announced that the U.S. Food and Drug Administration FDA has granted orphan drug designation to CK-3773274 CK-274 for the treatment of symptomatic hypertrophic cardiomyopathy HCM. CK-274 is a next-generation cardiac myosin inhibitor in development for the potential treatment of HCM. 